JAN 2017: In January 2017, the J&P MEDICAL RESEARCH Ltd. applied to the Horizon 2020 research funding program and was awarded “Seal of Excellence”. The Seal of Excellence is a quality label awarded to projects which were deemed to deserve funding but did not receive it due to budget limits. This quality label is a guarantee for investors to find high standard projects from European SMEs with strong feasibility and capacity of development.
Seal of Excellence Certificate
JUN 2016: We obtained the exclusive, non-transferable licensing rights from ICT Innovation in Clinical Trials GmbH. to develop, manufacture, practice and sell premierConsent® worldwide. premierConsent®, aims at providing better patient education and deeper insights into clinical trial activities for all stakeholders involved. premierConsent® will harmonize the delivery of essential information on risks and benefits of a clinical study across all study centers.
DEC 2015: Following the launch of “ICT Innovation in Clinical Trials GmbH.” in Vienna, Austria, in August 2015, we are delighted to now be partnering with this start-up life science company. The ICT GmbH. is committed to improving clinical trials in quality, design, safety and traceability during informed consent provision.
FEB 2013: J&P proudly announces the completion of a two-year FEMtech project that focused on the topic of gender mainstreaming and through that on the creation of equal opportunities at J&P MEDICAL RESEARCH Ltd. for women and men. Numerous initiatives were started to optimize processes within the company to generally increase support for our employees. J&P will continue to introduce new strategies for these important topics and will continue optimizing already implemented processes. Our informational leaflet summarizes our approach as well as our sincerity regarding gender mainstreaming.
SEP 2012: This month we are celebrating our 5th anniversary of foundation of the company. This is reason enough to point out that we were doing really good in the last years. Our research activities spread all over the EU and the US.
MAY 2011: We proudly announce that we have successfully submitted scientific development programs, which were considered highly innovative and conceptional for granting external funding by the "Österreichische Forschungsgesellschaft mbH (FFG/ FemTech Program)".
FEB 2011: We won first prize for most „Innovative Projects in Business Services 2010“ issued by the Federal Agency for Economy in Vienna (Wirtschaftsagentur Wien). This contest was truly a collaborative effort among local economic development and extra-academic research institutions, all working together to build regional growth through entrepreneurship and innovation. Photos.
NOV 2010: Encouraged physicians, who already hold their degree in medicine are invited to apply for residency in anesthesiology, dermatology, emergency medicine, internal medicine, neurology, gynecology, pathology, pediatrics, radiology, surgery, or other specialties. For more details please see "JOB-section".
OCT 2010: The quality management system (ISO 9001:2008) was successfully renewed and extended after 1 year of becoming effective.
SEP 2010: J&P MEDICAL RESEARCH Ltd. has been invited by the New York State Foundation for Science, Technology and Innovation (NYSTAR) to consider the opening of another branch office in New York. NYSTAR is a public benefit corporation that helps grow New York's innovation economy with its support of high technology development and commercialization through academic and business partnerships. Through existing programs and strategic initiatives NYSTAR promotes university/business partnerships to foster the advancement and commercialization of the most economically promising technologies of tomorrow.
SEP 2010: We are glad to announce that J&P MEDICAL RESEARCH Ltd. in cooperation with the Beth Israel Deaconess Medical Center and Harvard Medical School is presenting a poster at the 50th ICAAC meeting held from SEP. 12.-15., 2010 in Boston.
JUL 2010: The J&P MEDICAL RESEARCH Ltd. team feels great satisfaction realizing that we - in cooperation with our valued clients- have made many positive strides in the last months and have much to celebrate. While this is always gratifying, it is also a reminder for us that to remain leaders we must be vigilant in our efforts to propel the company and science forward, cognizant of our highly competitive environment, and be unrelenting in our creativity and commitment to excellence. As an example of our movement forward, we made considerable progress in the past year toward putting J&P MEDICAL RESEARCH Ltd. on more stable financial footing while at the same time advancing many of our key strategic priorities. We had to make some difficult choices, but these choices have created new opportunities.
MAY 2010: We are pleased to announce that J&P MEDICAL RESEARCH Ltd. and "Dr. Wieselhuber & Partner GmbH" have signed an agreement of close cooperation. This agreement is in keeping with our philosophy of partnering with high-quality management consultancies to offer the right services in the right location.
MAY 2010: During the 4th. Austrian Congress of Infectious Diseases (Saalfelden, Austria) from May 5.-8, 2010, reseachers of J&P MEDICAL RESEARCH Ltd. presented five different posters. Three of these five (pre)clinical studies were published shortly thereafter in high impact medical journals.
Poster 1, Poster 2, Poster 3, Poster 4, Poster 5
APR 2010: We offer the conduct and management of large, international, multicenter non-interventional studies in Europe according to current drug laws. Data entry and collection are performed via secured internet connection. For more details please see our NIS-website
JAN 2010: Dr. Joukhadar extended his affiliations to Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, US, for 2 more years.
JAN 2010: HAITI EARTHQUAKE VICTIMS AID PROJECT: We decided to donate 2.5% of our total annual sales in 2009 to the victims of the earthquake in Haiti.
JAN 2010: We opened a new database providing us access to a large subject population of different age groups for flu vaccine research and development programs.
OCT 2009: We closed an agreement of cooperation with NYCOMED GmbH, Constanze, GER.
SEP 2009: Part of our recent investigation was presented as a poster entitled " Lack of Bactericidal Antagonism or Synergism In-vitro Between Oxacillin and Vancomycin against Methicillin Susceptible Strains of Staphylococcus aureus" at 49th ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco, CA, USA from SEP 12-15, 2009. The respective article was electronically published ahead in the Journal of Antimicrobial Agents and Chemotherapy.
SEP 2009: Our institution received full certification according to ISO 9001:2008 criteria.
MAY 2009: We implemented a quality management system according to ISO 9001:2008, preparing for official certification in september 2009
JAN 2009: Dr. Christian Joukhadar, Chief Operating Officer of J&P MEDICAL RESEARCH Ltd. was the official representative of the Austrian Business Delegation and was an invited participant in the public panel discussion round on "Opportunities of US Entrepreneurs in Europe" This event was held at the Massachusetts Institutes of Technology (MIT) in Cambridge, MA, US.
JAN 2009: We closed agreements of cooperation with Harvard Medical School and the Massachusetts Institutes of Technology (MIT) in Boston and Cambridge US, respectively.
JAN 2009: Scientific and overall development of J&P MEDICAL RESEARCH Ltd. topped all expectations in 2008.